Winnipeg Free Press - PRINT EDITION

Medicines holding cancer at bay: study

Drugs help patients with breast tumours

SAN ANTONIO -- Breast cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get worse.

In a large international study, an experimental drug from Genentech called pertuzumab held cancer at bay for a median of 18 months when given with standard treatment, versus 12 months for others given only the usual treatment. It also strongly appears to be improving survival, and followup is continuing to see if it does.

"You don't see that very often. It's a spectacular result," said one study leader, Dr. Sandra Swain, medical director of the Washington Hospital Center's cancer institute.

In a second study, another drug long used in organ transplants but not tried against breast cancer -- everolimus, sold as Afinitor by Novartis AG -- kept cancer in check for a median of seven months in women whose disease was worsening despite treatment with hormone-blocking drugs. A comparison group that received only hormonal medicine had just a three-month delay in disease progression.

Afinitor works in a novel way, seems "unusually effective" and sets a new standard of care, said Dr. Peter Ravdin, breast cancer chief at the UT Health Science Center in San Antonio. He has no role in the work or ties to drugmakers. Most patients have tumours like those in this study -- their growth is fuelled by estrogen.

Results were released Wednesday at the San Antonio Breast Cancer Symposium and some were published online by the New England Journal of Medicine. They come a few weeks after federal approval was revoked for another Genentech drug, Avastin, that did not meaningfully help breast cancer patients.

The new drugs are some of the first major developments since Herceptin came out in 1998. It has become standard treatment for a certain type of breast cancer.

"These are powerful advances... an important step forward," said Dr. Harold Burstein, a breast cancer expert at Dana-Farber Cancer Institute in Boston who had no role in the studies.

A reality check: The new drugs are likely to be very expensive -- up to $10,000 a month -- and so far have not proved to be cures. Doctors hope they might be when given to women with early-stage cancers when cure is possible.

-- The Associated Press

Republished from the Winnipeg Free Press print edition December 8, 2011 A16

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is register and/or login and you can join the conversation and give your feedback.

Have Your Say

New to commenting? Check out our Frequently Asked Questions.

The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.

letters

Make text: Larger | Smaller

LATEST VIDEO

Claude Noel on the Jets' disappointing last game of the season

View more like this

Photo Store Gallery

  • A baby Red Panda in her area at the Zoo. International Red Panda Day is Saturday September 15th and the Assiniboine Park Zoo will be celebrating in a big way! The Zoo is home to three red pandas - Rufus, Rouge and their cub who was born on June 30 of this year. The female cub has yet to be named and the Assiniboine Park Zoo is asking the community to help. September 14, 2012  BORIS MINKEVICH / WINNIPEG FREE PRESS
  • Marc Gallant / Winnipeg Free Press. Local- Weather standup. Sundog. Refraction of light through ice crystals which caused both the sun dog and and fog along McPhillips Road early Wednesday morning. 071205.

View More Gallery Photos

Poll

Do you miss the era of drive-in movie theatres?

View Results

Ads by Google